Skip to content
Buy This GLP
← Research
Evidence

Does a Higher Semaglutide Dose Raise Mental Health Risk?

A large records study linked higher attained doses with fewer later diagnoses in several categories. It could not determine whether increasing the dose caused the difference.

Editorial profile: Carla MedinaBuy This GLP Editorial Team5 min read
Higher vs lower attained dose · Rate ratio (95% CI)Substance-related disorders0.71 (0.62–0.81)Mood or affective disorders0.82 (0.75–0.89)Anxiety and related disorders0.88 (0.81–0.94)Diagnoses recorded in years 3 and 4 after starting treatment

What the study measured

Murugadoss and colleagues studied 63,215 people with pre-existing neuropsychiatric conditions and evaluated 24 groups of new diagnoses in electronic health records [1]. Their separate dose analysis compared 39,795 semaglutide users whose highest dose in the first two years was 0.25–1.0 mg with 15,515 whose highest dose was 1.7, 2.0 or 2.4 mg. Researchers then counted diagnoses recorded during the following two years.

The investigators found lower recorded rates for substance-related disorders (rate ratio 0.71, 95% confidence interval 0.62–0.81), mood or affective disorders (0.82, 0.75–0.89), and anxiety and related disorders, including trauma-related disorders and OCD (0.88, 0.81–0.94). Other categories are listed in the full paper. The analysis did not detect a statistically clear difference for dementia or degenerative central nervous system diseases (P = 0.15).

Why reaching a higher dose matters

People who reach a higher dose may differ in treatment tolerance, access and how long they continue therapy. In a separate Vanderbilt obesity clinic program that covered prescribed medication costs, 81% of semaglutide users reached at least 1 mg and 23% reached 2.4 mg [3]. A Danish primary-care study on dose titration likewise illustrates how prescribing varied within one practice. That study tracked dose and weight, and the Vanderbilt figures describe how often patients reached certain doses.

Using separate windows for dose and outcomes helps establish the order of recorded events. Early symptoms could still affect who was able to increase their dose, and the analysis could miss symptoms that occurred during the first two years. The authors also reported that most outcomes did not differ clearly across weight-loss groups. The retrospective design limits what those findings can tell us about the causes of the observed differences. The authors worked for nference, which collaborates with drugmakers whose products were included, and reported that those collaborators had no role in or funding for the study [1].

How this fits with other evidence

The Swedish register study of four GLP-1 medicines examined worsening illness in people with existing depression or anxiety and recorded antidiabetic medication use. Its semaglutide estimate was an adjusted hazard ratio of 0.58 (95% CI 0.51–0.65) for a composite that included psychiatric hospitalization, extended psychiatric sick leave, hospitalization for self-harm and death by suicide [2]. That comparison was based on periods of medication use and non-use. A separate South Korean hospital cohort found more newly recorded depression and anxiety diagnoses among Wegovy initiators than among matched non-initiators. The populations, comparisons and outcomes differed, and each study was observational [4].

In the separate evidence on suicidal thoughts and behavior, the FDA found no increased risk of those outcomes and requested removal of the corresponding warning from Wegovy, Saxenda and Zepbound labeling [5]. The dose study answers a different question about recorded neuropsychiatric diagnoses.

Frequently asked

Does a higher semaglutide dose raise mental health risk?
One retrospective comparison found fewer later diagnoses in several categories among people who reached a higher dose. It cannot tell whether the dose caused the difference or how often symptoms occurred during early escalation.
How large was the difference for mood disorders?
The rate ratio for mood or affective disorders was 0.82 (95% confidence interval 0.75–0.89), comparing people who reached 1.7–2.4 mg with those who reached 0.25–1.0 mg.
Does this apply to Wegovy HD?
The dose analysis only included doses through 2.4 mg. Wegovy HD is a 7.2 mg formulation.
Should this study change my dose?
The study cannot support a dosing change for mental health. Discuss symptoms and any dose change with your prescriber.

Sources

  1. [1] Murugadoss K, et al. (2026). Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss npj Metabolic Health and Disease. PMID 42680805
  2. [2] Taipale H, et al. (2026). Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study The Lancet Psychiatry. PMID 41862258
  3. [3] Samuels JM, et al. (2025). Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic Diabetes, Obesity and Metabolism. PMID 40762026
  4. [4] Park J, et al. (2026). GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Diabetes, Obesity and Metabolism. PMID 42410329
  5. [5] U.S. Food and Drug Administration (2026). FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonists Drug Safety Communication. Source
  6. [6] U.S. Food and Drug Administration (2026). FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide FDA. Source

More in Evidence